HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

William G Lindsley Selected Research

Aerosols

1/2022Face mask fit modifications that improve source control performance.
1/2022Reduction of exposure to simulated respiratory aerosols using ventilation, physical distancing, and universal masking.
11/2021Sampling for SARS-CoV-2 Aerosols in Hospital Patient Rooms.
10/2021Bioaerosol Sampling for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a Referral Center with Critically Ill Coronavirus Disease 2019 (COVID-19) Patients March-May 2020.
7/2021Efficacy of Portable Air Cleaners and Masking for Reducing Indoor Exposure to Simulated Exhaled SARS-CoV-2 Aerosols - United States, 2021.
2/2021A comparison of performance metrics for cloth face masks as source control devices for simulated cough and exhalation aerosols.
1/2021Efficacy of universal masking for source control and personal protection from simulated cough and exhaled aerosols in a room.
1/2020Microbial Aerosols: New Diagnostic Specimens for Pulmonary Infections.
12/2019Efficacy of an ambulance ventilation system in reducing EMS worker exposure to airborne particles from a patient cough aerosol simulator.
10/2018Assessment of influenza virus exposure and recovery from contaminated surgical masks and N95 respirators.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


William G Lindsley Research Topics

Disease

18Human Influenza (Influenza)
02/2021 - 05/2007
16Cough
01/2022 - 11/2010
3COVID-19
11/2021 - 07/2021
2Infections
02/2021 - 01/2020
1Severe Acute Respiratory Syndrome
10/2021
1Critical Illness (Critically Ill)
10/2021

Drug/Important Bio-Agent (IBA)

23AerosolsIBA
01/2022 - 05/2007
3RNA (Ribonucleic Acid)IBA
10/2018 - 03/2010
2Viral RNAIBA
12/2011 - 11/2010
1human MIRN326 microRNAIBA
02/2021
1human MIRN885 microRNAIBA
02/2021
1Epidermal Growth Factor (EGF)IBA
02/2021
1InterferonsIBA
02/2021
1InterleukinsIBA
02/2021
1Proteins (Proteins, Gene)FDA Link
02/2021
1Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
02/2021
1Interleukin-15 (Interleukin 15)IBA
02/2021
1Interleukin-17 (Interleukin 17)IBA
02/2021
1MicroRNAs (MicroRNA)IBA
02/2021
1Interleukin-6 (Interleukin 6)IBA
02/2021
1Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
02/2021
1Granulocyte Colony-Stimulating Factor (G-CSF)IBA
02/2021
1CytokinesIBA
02/2021
1Bovine Serum AlbuminIBA
10/2018
1Aerosolized Particles and DropletsIBA
01/2018

Therapy/Procedure

4Mechanical Ventilators (Ventilator)
10/2018 - 01/2012
3N95 Respirators
10/2018 - 06/2012
1Braces
01/2022
1Hand Hygiene
01/2018
1Lasers (Laser)
01/2012